Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.

doi:10.1056/NEJMoa2306441

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.

The New England journal of medicine - 30 Nov 2023

Zhou Caicun, Tang Ke-Jing, Cho Byoung Chul, Liu Baogang, Paz-Ares Luis, Cheng Susanna, Kitazono Satoru, Thiagarajan Muthukkumaran, Goldman Jonathan W, Sabari Joshua K, Sanborn Rachel E, Mansfield Aaron S, Hung Jen-Yu, Boyer Michael, Popat Sanjay, Mourão Dias Josiane, Felip Enriqueta, Majem Margarita, Gumus Mahmut, Kim Sang-We, Ono Akira, Xie John, Bhattacharya Archan, Agrawal Trishala, Shreeve S Martin, Knoblauch Roland E, Park Keunchil, Girard Nicolas

Abstract excerpt

BACKGROUND: Amivantamab has been approved for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease progression during or after platinum-based chemotherapy. Phase 1 data showed the safety and antitumor activity of amivantamab plus carboplatin-pemetrexed (chemotherapy). Additional data on this combination...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carboplatin

Share to Carcinoma, Non-Small-Cell Lung

Share to Disease Progression

Share to ErbB Receptors

Share to Pemetrexed

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 37870976
DOI: 10.1056/NEJMoa2306441

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.PMID 37870976Read ↗

Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.Semantic proximity Read ↗

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.Semantic proximity Read ↗

FDA Approval Summary: Amivantamab for the Treatment of Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.Semantic proximity Read ↗

Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer.Semantic proximity Read ↗

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.Semantic proximity Read ↗

Spotlight on Amivantamab (JNJ-61186372) for EGFR Exon 20 Insertions Positive Non-Small Cell Lung CancerSemantic proximity Read ↗

Mobocertinib: A Potential Treatment for NSCLC with EGFR Exon 20 Insertions.Semantic proximity Read ↗

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.Semantic proximity Read ↗

EGFR Exon 20 insertions in NSCLC: from biology to amivantamab, optimal treatment strategy and emerging therapeutics.Semantic proximity Read ↗

Amivantamab and Mobocertinib in Exon 20 insertions EGFR Mutant Lung Cancer, Challenge To The Current GuidelinesSemantic proximity Read ↗

Targeted Therapies for EGFR Exon 20 Insertion Mutation in Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Targeting EGFR Exon 20 Insertion Mutation in Non-small cell Lung Cancer: Amivantamab and Mobocertinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.